Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

Ligand Q3 Royalty Revenue Rises 51% and 2026 EPS Guidance Raised

Oct 29, 2026, 7:21 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Raised EPS guidance amid solid Q3 royalties and reaffirmed revenue outlook reduce execution risk and may attract buyers ahead of or after the investor call.

AI summary

What happened, with direct paths to the underlying reporting

Ligand Pharmaceuticals reported a strong Q3, with royalty revenue up 51% YoY to $70.3 million and the company raising 2026 adjusted diluted EPS guidance to $9.50–$9.75, while reaffirming revenue guidance. The 8:30 a.m. ET investor call today signals ongoing confidence in its royalty-driven model and potential upside from partner milestones, supporting a constructive near-term outlook for LGND.

Q3 royalty revenue up 51% YoY to $70.3M. Raises 2026 adjusted diluted EPS to $9.50–$9.75.
Reaffirms 2026 revenue guidance; conference call at 8:30 a.m. ET today.
LGND strengthens earnings trajectory on higher guidance from robust royalty streams.
Watch royalty mix and partner milestones for potential upside catalysts.
Location noted as Jupiter, Florida, with investor call to discuss results.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.